NLRP3 participates in the differentiation and apoptosis of PMA‑treated leukemia cells

Wang,Yixian; Xin,Chunhong; Li,Xiaokun; Chang,Xiaoxia; Jiang,Ru

doi:10.3892/mmr.2023.13039

NLRP3 participates in the differentiation and apoptosis of PMA‑treated leukemia cells

Authors:
- Yixian Wang
- Chunhong Xin
- Xiaokun Li
- Xiaoxia Chang
- Ru Jiang
View Affiliations

Affiliations: Intensive Care Unit, Muping Hospital of Traditional Chinese Medicine, Yantai, Shandong 264100, P.R. China, Department of Hematopathology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, P.R. China, Department of Emergency Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, P.R. China, Department of Cardiology, Muping Hospital of Traditional Chinese Medicine, Yantai, Shandong 264100, P.R. China, Department of Laboratory Medicine, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong 264100, P.R. China
Published online on: June 21, 2023 https://doi.org/10.3892/mmr.2023.13039
Article Number: 152
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) is a clonal malignant proliferative disease. In recent years, with the use of all‑trans retinoic acid to induce cancer cell differentiation in acute promyelocytic leukemia, and its advantages of high efficacy and low toxic side effects, tumor differentiation therapy has become a research hotspot; however, the mechanisms underlying its role remain to be fully established. Nod‑like receptor family pyridine domain containing 3 (NLRP3) is the most extensively studied and well‑characterized inflammasome, is involved in a variety of inflammation‑related diseases, including cancer, and is a very attractive potential target for the study of novel therapeutic agents. Activation of the NLRP3 inflammasome is a double‑edged sword in tumor therapy, with evidence of protective anti‑tumor and pro‑tumor effects in different types of cancer. Whether the NLRP3 inflammasome promotes disease progression or exerts a protective anti‑tumor effect in hematological malignancies remains contested. In the present study, the protective anti‑tumor effects of NLRP3 on leukemia cells during their differentiation and maturation were investigated. It was found that the upregulation of NLRP3 expression induced using Phorbol 12‑Myristate 13‑Acetate played a role in promoting the differentiation and maturation of leukemia cells into monocytes/macrophages, and it was directly involved in the apoptosis of leukemia cells and the differentiation and maturation of CD11b⁺ cells. These results provide novel theoretical evidence for exploring the mechanism of differentiation therapy in leukemia and improves our understanding of the role of NLRP3 in hematologic tumors.

View Figures

View References

1	Stahl M and Tallman MS: Acute promyelocytic leukemia (APL): Remaining challenges towards a cure for all. Leuk Lymphoma. 60:3107–3115. 2019. View Article : Google Scholar : PubMed/NCBI
2	Su R, Qing Y and Chen J: Targeting differentiation blockade in AML: New hope from cell-surface-based CRISPR screens. Cell Stem Cell. 28:585–587. 2021. View Article : Google Scholar : PubMed/NCBI
3	He Y, Hara H and Núñez G: Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 41:1012–1021. 2016. View Article : Google Scholar : PubMed/NCBI
4	Martinon F, Burns K and Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 10:417–426. 2002. View Article : Google Scholar : PubMed/NCBI
5	Vince JE and Silke J: The intersection of cell death and inflammasome activation. Cell Mol Life Sci. 73:2349–2367. 2016. View Article : Google Scholar : PubMed/NCBI
6	Gaidt MM and Hornung V: The NLRP3 inflammasome renders cell death Pro-inflammatory. J Mol Biol. 430:133–141. 2018. View Article : Google Scholar : PubMed/NCBI
7	Zheng M, Williams EP, Malireddi RKS, Karki R, Banoth B, Burton A, Webby R, Channappanavar R, Jonsson CB and Kanneganti TD: Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection. J Biol Chem. 295:14040–14052. 2020. View Article : Google Scholar : PubMed/NCBI
8	Hamarsheh S, Osswald L, Saller BS, Unger S, De Feo D, Vinnakota JM, Konantz M, Uhl FM, Becker H, Lübbert M, et al: Oncogenic Kras^G12D causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun. 11:16592020. View Article : Google Scholar : PubMed/NCBI
9	Liu Q, Hua M, Zhang C, Wang R, Liu J, Yang X, Han F, Hou M and Ma D: NLRP3-activated bone marrow dendritic cells play antileukemic roles via IL-1β/Th1/IFN-γ in acute myeloid leukemia. Cancer Lett. 520:109–120. 2021. View Article : Google Scholar : PubMed/NCBI
10	Sauter KA, Wood LJ, Wong J, Iordanov M and Magun BE: Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther. 11:1008–1016. 2011. View Article : Google Scholar : PubMed/NCBI
11	Westbom C, Thompson JK, Leggett A, MacPherson M, Beuschel S, Pass H, Vacek P and Shukla A: Inflammasome modulation by chemotherapeutics in malignant mesothelioma. PLoS One. 10:e01454042015. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Myou S, Zhu X, Boetticher E, Qin Y, Myo S, Meliton A, Lambertino A, Munoz NM, Hamann KJ and Leff AR: Regulation of adhesion of AML14.3D10 cells by surface clustering of beta2-integrin caused by ERK-independent activation of cPLA2. Immunology. 107:77–85. 2002. View Article : Google Scholar : PubMed/NCBI
14	Lam CF, Yeung HT, Lam YM and Ng RK: Reactive oxygen species activate differentiation gene transcription of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway. Leuk Res. 68:112–119. 2018. View Article : Google Scholar : PubMed/NCBI
15	Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
16	Yates JW, Wallace HJ Jr, Ellison RR and Holland JF: Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 57:485–488. 1973.PubMed/NCBI
17	Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 369:111–121. 2013. View Article : Google Scholar : PubMed/NCBI
18	Swanson KV, Deng M and Ting JP: The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat Rev Immunol. 19:477–489. 2019. View Article : Google Scholar : PubMed/NCBI
19	Huang Y, Xu W and Zhou R: NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 18:2114–2127. 2021. View Article : Google Scholar : PubMed/NCBI
20	Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC and Salter RD: Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol. 191:5230–5238. 2013. View Article : Google Scholar : PubMed/NCBI
21	Sorbara MT and Girardin SE: Mitochondrial ROS fuel the inflammasome. Cell Res. 21:558–560. 2011. View Article : Google Scholar : PubMed/NCBI
22	Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, Vetter I, Dungan LS, Monks BG, Stutz A, et al: A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 21:248–255. 2015. View Article : Google Scholar : PubMed/NCBI
23	Sharma BR and Kanneganti TD: NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. 22:550–559. 2021. View Article : Google Scholar : PubMed/NCBI
24	Guo B, Fu S, Zhang J, Liu B and Li Z: Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep. 6:361072016. View Article : Google Scholar : PubMed/NCBI
25	Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J and Yazdi AS: Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci USA. 109:18384–18389. 2012. View Article : Google Scholar : PubMed/NCBI
26	Dunn JH, Ellis LZ and Fujita M: Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett. 314:24–33. 2012. View Article : Google Scholar : PubMed/NCBI
27	Daley D, Mani VR, Mohan N, Akkad N, Pandian GSDB, Savadkar S, Lee KB, Torres-Hernandez A, Aykut B, Diskin B, et al: NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med. 214:1711–1724. 2017. View Article : Google Scholar : PubMed/NCBI
28	Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al: Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 15:1170–1178. 2009. View Article : Google Scholar : PubMed/NCBI
29	Dupaul-Chicoine J, Arabzadeh A, Dagenais M, Douglas T, Champagne C, Morizot A, Rodrigue-Gervais IG, Breton V, Colpitts SL, Beauchemin N and Saleh M: The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity. 43:751–763. 2015. View Article : Google Scholar : PubMed/NCBI
30	Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W Jr, Murphy AJ, et al: IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 491:259–263. 2012. View Article : Google Scholar : PubMed/NCBI
31	van Deventer HW, Burgents JE, Wu QP, Woodford RM, Brickey WJ, Allen IC, McElvania-Tekippe E, Serody JS and Ting JP: The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 70:10161–10169. 2010. View Article : Google Scholar : PubMed/NCBI
32	Karki R and Kanneganti TD: Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer. 19:197–214. 2019. View Article : Google Scholar : PubMed/NCBI
33	Wang J, Liu L, Xie L, Xiang G and Zhou Y: Induction of differentiation-specific miRNAs in TPA-induced myeloid leukemia cells through MEK/ERK activation. Int J Mol Med. 31:59–66. 2013. View Article : Google Scholar : PubMed/NCBI
34	Daigneault M, Preston JA, Marriott HM, Whyte MK and Dockrell DH: The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS One. 5:e86682010. View Article : Google Scholar : PubMed/NCBI
35	Maeß MB, Wittig B, Cignarella A and Lorkowski S: Reduced PMA enhances the responsiveness of transfected THP-1 macrophages to polarizing stimuli. J Immunol Methods. 402:76–81. 2014. View Article : Google Scholar : PubMed/NCBI
36	Park EK, Jung HS, Yang HI, Yoo MC, Kim C and Kim KS: Correction to: Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res. 69:11572020. View Article : Google Scholar : PubMed/NCBI
37	Aldo PB, Craveiro V, Guller S and Mor G: Effect of culture conditions on the phenotype of THP-1 monocyte cell line. Am J Reprod Immunol. 70:80–86. 2013. View Article : Google Scholar : PubMed/NCBI
38	Faria SS, Costantini S, de Lima VCC, de Andrade VP, Rialland M, Cedric R, Budillon A and Magalhães KG: NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. J Biomed Sci. 28:262021. View Article : Google Scholar : PubMed/NCBI
39	Teng JF, Mei QB, Zhou XG, Tang Y, Xiong R, Qiu WQ, Pan R, Law BY, Wong VK, Yu CL, et al: Polyphyllin VI induces Caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer. Cancers (Basel). 12:1932020. View Article : Google Scholar : PubMed/NCBI
40	Xia X, Wang X, Cheng Z, Qin W, Lei L, Jiang J and Hu J: The role of pyroptosis in cancer: pro-cancer or pro-‘host’ ? Cell Death Dis. 10:6502019. View Article : Google Scholar : PubMed/NCBI